Nancy Holekamp's guest appearances

Nancy Holekamp

Straight From The Cutter's Mouth: A Retina Podcast

MedEdTalks - Ophthalmology

Foundation Fighting Blindness

Arshad Khanani

Lisa Nijm

Judy Kim

Carl Regillo

Michael Stone

Michael Cohen

Richard Parrish

Michael Lee

Stephen Russell

Gordon Gund

Adrienne Scott

Andrew Lee

Sarah Read

Daniel Chao

Jim Dahle

OwlTail

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Nancy Holekamp discuss the efficacy and safety of therapies targeting Ang-2 in DME.

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Nancy Holekamp discuss the efficacy and safety of therapies targeting Ang-2 in DME.

Targeting Angiopoietin-2 in DME: Efficacy and Safety Data With Drs. Carl Regillo and Nancy Holekamp

March 11, 2022. Dr. Nancy Holekamp, a retinal specialist, clinical trial investigator, and key opinion leader in the retinal disease space, discusses new therapies and research for wet and dry age-related macular degeneration and some emerging treatment approaches for inherited retinal diseases.This episode is sponsored by Apellis Pharmaceuticals.

March 11, 2022. Dr. Nancy Holekamp, a retinal specialist, clinical trial investigator, and key opinion leader in the retinal disease space, discusses new therapies and research for wet and dry age-related macular degeneration and some emerging treatment approaches for inherited retinal diseases. This episode is sponsored by Apellis Pharmaceuticals.

Eye on the Cure Podcast | Episode 20: Dr. Nancy Holekamp

Dr. Nancy Holekamp joins the program to discuss her career development, the paradigm shift in terms of management of persistent subretinal fluid in wet age-related macular degeneration, strategies for improving AMD treatment including the port-delivery system and gene therapy, and her role in founding Women in Retina (WinR).Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Dorc, Oxurion, and Regeneron. Dr. Holekamp has received consulting fees from Allergan, Acucela, Apellis, Lineage Cell Therapeutics, Clearside Biosciences, Gemini, Genentech, Gyroscope, Katalyst Surgical, Nacuity, Notal Vision, Novartis, Polyactiva, and Regeneron. She is on the Speaker's Bureau for Allergan, Genentech, Novartis, Regeneron, and Spark. She performs contracted research with Genentech, Gemini, and Gyroscope and holds an intellectual property patent with Katalyst Surgical.

Dr. Nancy Holekamp joins the program to discuss her career development, the paradigm shift in terms of management of persistent subretinal fluid in wet age-related macular degeneration, strategies for improving AMD treatment including the port-delivery system and gene therapy, and her role in founding Women in Retina (WinR). Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Dorc, Oxurion, and Regeneron. Dr. Holekamp has received consulting fees from Allergan, Acucela, Apellis, Lineage Cell Therapeutics, Clearside Biosciences, Gemini, Genentech, Gyroscope, Katalyst Surgical, Nacuity, Notal Vision, Novartis, Polyactiva, and Regeneron. She is on the Speaker's Bureau for Allergan, Genentech, Novartis, Regeneron, and Spark. She performs contracted research with Genentech, Gemini, and Gyroscope and holds an intellectual property patent with Katalyst Surgical.

Episode 262: Strategies for Treating Wet Age-Related Macular Degeneration and more with Dr. Nancy Holekamp